Top 3 Picks
2026 Outlook
Sector trends through 2026 point to accelerated adoption of AI-driven molecular diagnostics and expanded oncology testing pipelines, supported by R&D spending growth. Small- and mid-cap firms with scores above 50 are positioned for revenue expansion via clinical advancements and potential partnerships. Overall, the sector could see 8-12% compounded growth as regulatory pathways streamline approvals for next-gen assays.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Immucell Corp
|
67.5 | $9.90 | $60M |
|
2
|
Celldex Therapeutics, Inc
|
62.9 | $39.68 | $1.7B |
|
3
|
Insight Molecular Diagnostics Inc. Common Stock
|
59.0 | $4.13 | $94M |
|
4
|
Myriad Genetics Inc
|
53.1 | $3.19 | $719M |
|
5
|
Neogen Corp
|
52.7 | $11.83 | $1.3B |
|
6
|
Lantheus Holdings, Inc
|
51.7 | $100.97 | $3.5B |
|
7
|
Idexx Laboratories Inc
|
48.3 | $535.38 | $49.6B |
|
8
|
Intellia Therapeutics, Inc
|
46.3 | $12.74 | $2.0B |
|
9
|
QuidelOrtho Corporation Common Stock
|
44.7 | $13.97 | $2.1B |
|
10
|
VolitionRX Limited Common Stock
|
43.1 | $0.35 | $67M |
|
11
|
Cardio Diagnostics Holdings Inc. Common stock
|
40.7 | $1.86 | $8M |
|
12
|
Alpha Teknova, Inc. Common Stock
|
38.9 | $6.92 | $341M |
|
13
|
Q/C Technologies, Inc. Common Stock
|
37.7 | $1.79 | $8M |
|
14
|
Cardio Diagnostics Holdings Inc. Warrant
|
36.7 | $0.02 | -- |
|
15
|
Achieve Life Sciences, Inc.
|
35.1 | $8.49 | $158M |
In-Depth Analysis: Top Diagnostics Stocks
ICCC
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn …
ImmuCell Corp advances livestock diagnostics within the broader Diagnostics sector via its Scours segment products that enable early disease detection in dairy and beef cattle, directly supporting herd productivity and reducing economic losses from outbreaks.
ICCC reports a slim 2.6% profit margin and 2.6% ROE alongside 11.5% revenue growth, reflecting limited earnings conversion despite top-line gains, while the 142.9 P/E ratio signals market pricing for future margin recovery that remains unrealized.
Revenue expansion at 11.5% combined with a 67.5/100 Tradestie Score positions ICCC for potential 2026 upside as livestock diagnostic adoption grows in the dairy sector. Scaling the Scours portfolio could lift the current 2.6% ROE and margins if operating leverage materializes. Attractive entry for investors seeking exposure to animal health diagnostics with improving volume trends.
CLDX
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing …
Celldex Therapeutics advances cancer-targeting biologics and immunotherapy technologies relevant to diagnostic-informed oncology treatments, supporting clinical trials in breast cancer and metastatic melanoma within the broader Diagnostics sector ecosystem.
With ROE at -43.9% and revenue growth at -97.0%, Celldex exhibits severe unprofitability and sharp top-line contraction, signaling strained financial health reliant on external funding.
The Tradestie Score of 62.9/100 reflects moderate market positioning that could improve with 2026 trial readouts in lung cancer and melanoma. Positive data from its immunotherapy pipeline may drive revenue recovery and valuation upside for growth-oriented investors. High-risk biotech exposure offers asymmetric returns if commercialization milestones are achieved.
IMDX
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic …
Insight Molecular Diagnostics Inc. matters in the Diagnostics sector through its dd-cfDNA quantification technology designed to expand access to molecular testing for transplant monitoring and improve patient outcomes.
IMDX shows acute financial distress with ROE at -23603.1% and revenue contracting 53.9%, reflecting deep operating losses and negative cash generation.
Investors could target IMDX in 2026 if dd-cfDNA adoption accelerates in transplant diagnostics and reverses the -53.9% revenue trend. The 59.0/100 Tradestie Score leaves room for re-rating on technology commercialization milestones. Sector demand for accessible molecular biomarkers supports potential margin recovery from current levels.
MYGN
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to …
Myriad Genetics Inc matters in the Diagnostics sector as a molecular diagnostics provider offering the MyRisk 48-gene panel that identifies elevated risk for 11 cancer types, supporting personalized genetic testing services.
Myriad Genetics reports a profit margin of -41.3%, ROE of -23.5%, and revenue growth of -20.8%, indicating ongoing losses, negative returns on equity, and contracting top-line performance.
Investors may consider MYGN in 2026 if the company expands its MyRisk and other genetic panels amid rising precision oncology demand, potentially reversing the -20.8% revenue decline through new test adoption and operational leverage. A Tradestie Score of 53.1/100 reflects moderate positioning that could improve with margin recovery from current -41.3% levels. Growth in molecular diagnostics for hereditary cancer risk assessment offers a pathway to positive ROE.
NEOG
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged …
Neogen Corporation matters in the Diagnostics sector as a provider of specialized tests that detect pathogens and unintended substances in food and animal feed, directly supporting prevention of foodborne illnesses across global supply chains.
With a profit margin of -0.9% and ROE of -0.4%, Neogen shows current unprofitability, while revenue growth of -0.1% indicates limited top-line momentum and pressure on overall financial health.
Neogen's Tradestie Score of 52.7/100 leaves room for upside if food safety diagnostics demand accelerates with stricter regulations by 2026; recovery from -0.9% margins through operational efficiencies in animal safety could expand ROE beyond -0.4%; investors may target the stock for potential re-rating as revenue growth exits the -0.1% range amid sector consolidation.
LNTH
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic …
Lantheus Holdings matters in the Diagnostics sector as a US-focused provider of precision diagnostics and radiopharmaceutical oncology products across its three categories, enabling key imaging and oncology applications for healthcare providers.
LNTH shows solid financial health with a 17.7% profit margin and 22.2% ROE, reflecting efficient operations, though 2.7% revenue growth and a 24.2 P/E suggest measured expansion at current valuations.
Investors should consider LNTH in 2026 for potential upside from its radiopharmaceutical oncology and strategic partnerships segments, which could accelerate beyond the current 2.7% revenue growth. Strong 22.2% ROE and 17.7% margins position the company to capture share in expanding US diagnostics demand while maintaining a reasonable 24.2 P/E.
IDXX
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet …
IDEXX Laboratories dominates the veterinary diagnostics segment of the broader diagnostics sector through its in-office canine and feline test kits plus benchtop chemistry and hematology analyzers that deliver rapid results for pets and livestock.
IDEXX posts a 25.0% profit margin alongside an industry-leading 74.2% ROE, reflecting strong operational leverage and capital efficiency, while 9.7% revenue growth supports the 37.2 P/E valuation.
Rising companion-animal ownership and livestock health spending should sustain IDEXX's recurring test-kit and analyzer revenues through 2026. Its 25.0% margins and 74.2% ROE provide substantial earnings power to offset the 37.2 P/E multiple. Continued 9.7% top-line expansion positions the stock for multiple expansion if diagnostic utilization trends accelerate.
NTLA
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in …
Intellia Therapeutics advances CRISPR/Cas9 gene editing for precise genetic modifications, enabling targeted therapeutic development that supports diagnostic precision in identifying and addressing genetic disorders.
ROE of -55.4% and revenue contraction of -46.2% reflect ongoing net losses and operational challenges, with the Tradestie Score of 46.3/100 underscoring limited financial stability.
CRISPR platform advancements could drive clinical milestones by 2026, potentially reversing revenue trends through new therapeutic approvals. The moderate Tradestie Score leaves upside if pipeline data improves execution metrics. Investors may benefit from sector tailwinds in gene-based diagnostics as adoption scales.
QDEL
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue …
QuidelOrtho Corporation plays a vital role in the Diagnostics sector through its rapid diagnostic testing solutions in immunoassay, molecular testing, clinical chemistry, and transfusion medicine, enabling critical global healthcare decisions.
The company's profit margin of -39.2% and ROE of -45.9% highlight substantial profitability challenges and weak financial health, even as revenue growth stands at 2.8%.
Investors may consider QDEL for 2026 due to its established position in essential diagnostics amid potential sector recovery. The modest revenue growth of 2.8% signals underlying demand stability, and with a Tradestie Score of 44.7/100 indicating room for improvement, operational efficiencies could drive future gains.
VNRX
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying …
VolitionRX matters in the Diagnostics sector through its Nucleosomics platform, which develops cost-effective blood tests for cancer diagnosis and monitoring of NETo-associated diseases via epigenetics.
VolitionRX shows acute profitability challenges with an ROE of -730.1% and revenue growth of -2.0%, signaling ongoing losses and deteriorating financial health.
Investors may consider VNRX in 2026 for its potential to scale Nucleosomics-based tests in diagnostics as commercialization advances. The Tradestie Score of 43.1/100 provides a baseline for upside if revenue growth reverses from -2.0%. Successful platform adoption could improve margins despite current metrics.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.